Pro108 Antibody Compositions and Methods of Use and Use of Pro108 to Assess Cancer Risk

Abstract

A method for assessing risk of prostate cancer utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination is provided. Also provided is a method for assessing risk of cancer utilizing Pro108 or specific antibodies to Pro108. Antibodies that bind to Pro108 on a mammalian cell in vivo and compositions comprising an anti-Pro108 antibody and a carrier which can be provided in an article of manufacture or a kit are also provided. An isolated nucleic acid encoding an anti-Pro108 antibody, an expression vector comprising the isolated nucleic acid, cells that produce the anti-Pro108 antibodies and a method of producing the anti-Pro108 antibodies as well as methods for use of the antibodies in killing an Pro108-expressing cancer cell and alleviating or treating an Pro108-expressing cancer in a mammal are also provided.

1 . A method for assessing risk of cancer in a patient which comprises measuring levels of Pro108 in the patient to assess the risk of cancer in the patient, wherein an elevated level of Pro108 as compared to a control is indicative of heightened risk for cancer wherein Pro108 comprises residues 1-331 of SEQ ID NO:1 or SEQ ID NO:2 and Pro108 is measured with an antibody selected from:
 (i) an isolated antibody or antigen binding fragment specific for Pro108 produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886; or   (ii) an isolated antibody or antigen binding fragment which competes for binding to the same epitope of Pro108 recognized by the antibody produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886.   
     
     
         2 . The method of  claim 1  wherein the cancer is selected from the group consisting of prostate, ovarian, colon, breast and stomach cancer. 
     
     
         3 . The method of  claim 2  wherein the cancer is prostate, ovarian or colon cancer. 
     
     
         4 - 7 . (canceled) 
     
     
         8 . A kit for determining the likelihood of a patient having cancer which comprises a suitable assay for measuring Pro108 levels with an antibody selected from:
 (i) an isolated antibody or antigen binding fragment specific for Pro108 produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886; or   (ii) an isolated antibody or antigen binding fragment which competes for binding to the same epitope of Pro108 recognized by the antibody produced by a hybridoma selected from the group consisting of ATCC Accession Number PTA-5885 and PTA-5886.   
     
     
         9 . The kit of  claim 8  wherein the cancer is selected from the group consisting of prostate, ovarian, colon, breast and stomach cancer. 
     
     
         10 . The kit of  claim 9  wherein the cancer is prostate, ovarian or colon cancer. 
     
     
         11 - 95 . (canceled) 
     
     
         96 . The method of  claim 1 , wherein the antibody that competes for binding to the same epitope is a monoclonal antibody, humanized antibody or human antibody. 
     
     
         97 . The method of  claim 96  wherein the antibody is a labeled antibody. 
     
     
         98 . The method of  claim 1  wherein PRO108 is measured in a sample selected from the group consisting of cells, tissues, blood, serum, plasma, urine, stool, salvia and sputum. 
     
     
         99 . The kit of  claim 8 , wherein the antibody that competes for binding to the same epitope is a monoclonal antibody, humanized antibody or human antibody. 
     
     
         100 . The kit of  claim 99  wherein the antibody is a labeled antibody.